A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy VersusPembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and WithoutActionable Genomic Alterations (TROPION-Lung10) - D7632C00001

AstraZeneca AB0 个研究点目标入组 675 人开始时间: 2024年3月11日最近更新: 2024年7月22日

试验速览

暂无简介。

•Histologically or cytologically documented non-squamous NSCLC., Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation., Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and abscence of documented local test result for any other known genomic alteration for which there are locally approved targeted first-line therapies., Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers., Known tumour PD-L1 expression status defined as TC = 50%, determined prospectively using the VENTANA PD-L1 (SP263) Assay., At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline., ECOG performance status of 0 or 1, Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention.

•Prior systemic therapy for advanced/metastatic NSCLC., History of leptomeningeal carcinomatosis, Known clinically significant corneal disease, Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled, History of active primary immunodeficiency, Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant., History of another primary malignancy within 3 years., Active or prior documented autoimmune or inflammatory disorders (with exceptions)., Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease., Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage., History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening, Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses., Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.

发起方